Maintenance notice in CEST time zone (1:00 - 3:30 AM May 17, 2026): Our website is scheduled for maintenance. The website will be available, but some functions may experience errors. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 54965-24-1 | Product Number: T2510
Tamoxifen Citrate
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (Z)-1-(4-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene Citrate
Product Documents:
| Size | Unit Price | Belgium | Japan* |
Shipping Information
|
|---|---|---|---|---|
| 1G |
83,00 €
|
3 | 15 | |
| 5G |
287,00 €
|
1 | ≥40 |
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | T2510 |
Purity / Analysis Method 
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__6H__2__9NO·C__6H__8O__7 = 563.65 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Light Sensitive,Hygroscopic,Heat Sensitive |
| Packaging and Container
|
1G-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 54965-24-1 |
| Related CAS RN
|
10540-29-1 |
| Reaxys Registry Number | 8888650 |
| PubChem Substance ID | 87560062 |
| Merck Index (14) | 9048 |
| MDL Number | MFCD00058321 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
Properties (reference)
| Melting Point | 142 °C(dec.) |
| Solubility in water | Slightly soluble |
| Solubility (soluble in) | Acetone, Ethanol, Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H350 : May cause cancer. |
| Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
Related Laws:
| EC Number | 259-415-2 |
| RTECS# | KH2387000 |
Transport Information:
| HS Number | 2921490090 |
Application
Tamoxifen Citrate: Selective Estrogen Receptor Modulator (SERM)
Tamoxifen citrate is a widely used nonsteroidal anti-estrogen agent for the treatment of hormone-dependent breast cancer. Tamoxifen is a prodrug and extensively metabolized by cytochrome P450 (CYP450) enzymes into active metabolites including 4-hydroxytamoxifen [H1693] and endoxifen (4-hydroxy-N-desmethyltamoxifen). Each acts as an estrogen receptor antagonist in breast tissue. Tamoxifen is commonly referred to as a selective estrogen receptor modulator (SERM), since it behaves as an estrogen receptor agonist in other tissues. (The product is for research purpose only.)
References
- Tamoxifen in the treatment of breast cancer
- Tamoxifen, raloxifene, and the prevention of breast cancer
- Mechanisms of tamoxifen-induced apoptosis
- Mechanisms of tamoxifen resistance
- CYP2D6 and tamoxifen: DNA matters in breast cancer
Application
Tamoxifen Citrate: Selective Estrogen Receptor Modulator (SERM)
Tamoxifen citrate is a widely used nonsteroidal anti-estrogen agent for the treatment of hormone-dependent breast cancer. Tamoxifen is a prodrug and extensively metabolized by cytochrome P450 (CYP450) enzymes into active metabolites including 4-hydroxytamoxifen and endoxifen (4-hydroxy-N-desmethyltamoxifen). They act as an estrogen receptor antagonist in breast tissue. Tamoxifen is commonly referred to as a selective estrogen receptor modulator (SERM), since it behaves as an estrogen receptor agonist in other tissues. (The product is for research purpose only.)
References
- Tamoxifen in the treatment of breast cancer
- Tamoxifen, Raloxifene, and the Prevention of Breast Cancer
- Mechanisms of tamoxifen-induced apoptosis
- Mechanisms of tamoxifen resistance
- CYP2D6 and tamoxifen: DNA matters in breast cancer
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.